Close X
Get more out of
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.

Click here if you're interested
Helping you make better health choices

What Doctors Don't Tell You

In shops now or delivered to your home from only £3.50 an issue!

January 2020 (Vol. 4 Issue 11)

Anti-aging antioxidant tested in major new trial
About the author: 

Anti-aging antioxidant tested in major new trial image

MitoQ, the world`s first mitochondrial-targeted antioxidant formula, is being tested for its anti-aging qualities in a prestigious new trial.

It`s been selected by the US`s National Institute of Aging alongside other remedies such as rapamycin and aspirin, which are also supposed to have anti-aging qualities.

The compounds will be tested for between three and five years for their significant potential to delay or decelerate the aging process and improve general health, said principal researcher Randy Strong, at the Texas Health Science Center at San Antonio. The NIA is part of the National Institute of Health, which invests more than $30bn a year in health research.
The results will be published in 2020 in major scientific journals such as Nature, Journals of Gerontology and Aging Cell.

MitoQ is supposed to optimise mitochondria often described as the powerhouse within cells by flooding them with antioxidants, and especially CoQ10. Greg Macpherson, managing director of MitoQ in New Zealand, said: Mitochondria are intricately linked to the aging process. If we can improve the way they function and slow free-radical leakage, we may slow down the aging process and keep all of our organs and body healthier and younger for longer.

MitoQ is a molecule developed more than 15 years ago by Dr Mike Murphy and Rob Smith at Otago University, New Zealand. There have been 200 published research papers on the compound, and two human trials are underway.

Support WDDTY

Help support us to hold the drugs companies, governments and the medical establishment accountable for what they do.


Latest Tweet


Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions..

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

© 2010 - 2019 WDDTY Publishing Ltd.
All Rights Reserved